MIAMI BEACH, Fla., March 07, 2024 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the “Company”), a national provider of premium body contouring procedures, today announced that management will be participating at the upcoming BofA Consumer and Retail Conference in Miami Beach on March 13, 2024. Please contact your BofA Securities representative for additional information.
About AirSculpt
AirSculpt is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin, while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results.
Investor Contact
Steven Halper
Managing Director, LifeSci Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Stephanie Evans Greene
Chief Marketing Officer
AirSculpt Technologies, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$10.82 |
| Daily Change: | -0.08 -0.73 |
| Daily Volume: | 382,007 |
| Market Cap: | US$675.600M |
May 02, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
